Global markets feel pulled between firm inflation, shifting central bank signals and uneven growth data. Bond yields in the US, UK and Europe keep pressure on valuations, while export powerhouses like South Korea highlight how specific growth stories can still stand out. In this mix, many investors seek companies where analysts see healthy earnings growth potential and balance sheets that look resilient. That is what the Healthy high growth potential screener targets. In this article, you will see 3 stocks from the screener that analysts currently view as some of the strongest opportunities to research further.

Alignment Healthcare (ALHC)

Overview: Alignment Healthcare runs a consumer focused healthcare platform that offers Medicare Advantage plans tailored for seniors across the United States, aiming to coordinate care more efficiently and lower medical costs. Founded in 2013 and based in Orange, California, the company uses technology, data and provider partnerships to manage members' health needs.

Market Cap: US$3.1b

Alignment Healthcare stands out if you are looking at companies where growth expectations and business model line up in a clear way. Analysts currently forecast revenue and earnings expansion, supported by a technology heavy care model, rising membership and industry leading Star Ratings that support richer reimbursement. At the same time, the stock trades below Simply Wall St’s DCF estimate. This suggests the market is treating regulatory risk, competition in Medicare Advantage and recent reinvestment in AI and clinical infrastructure with caution. The recent addition to several S&P indices and the company’s shift to profitability have put it on more investors’ radar; however, the full picture on margins, regulation and valuation is more nuanced than the headline growth story suggests.

Alignment Healthcare’s tech heavy Medicare Advantage model, index inclusion and move to profitability could mean the current skepticism is masking the full story. See how the market’s caution compares with the analyst forecasts for Alignment Healthcare

Corcept Therapeutics (CORT)

Overview: Corcept Therapeutics is a biopharmaceutical company that develops and commercializes cortisol modulating drugs, including Korlym for Cushing’s syndrome and a growing pipeline targeting endocrinologic, oncologic, metabolic and neurologic disorders in the United States.

Market Cap: US$12.8b

Corcept Therapeutics is attracting attention because it is shifting from dependence on Korlym toward a broader franchise in endocrinology and oncology, with Lifyorli already contributing to record revenue and relacorilant moving toward an FDA decision in Cushing’s syndrome in December 2026. Analysts describe potential for higher earnings, revenue and future return on equity over the next few years, but recent margin compression, a high valuation on some metrics and ongoing patent and pricing pressures keep risk firmly on the table. For investors who want exposure to a focused drug developer that is already generating substantial revenue yet still faces meaningful regulatory and legal hurdles, the full Corcept story is much more complex than the recent share price strength suggests.

Corcept Therapeutics is rapidly evolving from a single-drug story to a broader cortisol and oncology platform, while the market debate around earnings power, valuation and legal risk remains wide open. See what that tug of war looks like in the analysis report for Corcept Therapeutics

Coursera (COUR)

Overview: Coursera is an online learning company that partners with universities and employers to deliver courses, certificates and full degrees across business, technology and data science to individuals and organizations worldwide. It serves both consumers and institutional customers through subscriptions and tailored programs for businesses, campuses and governments.

Operations: Coursera generates most of its revenue from Consumer activities including Degrees at US$549.9m, with a further US$335.5m from its Enterprise segment.

Market Cap: US$1.5b

Coursera gives you direct exposure to the global shift toward online upskilling and professional certificates, while still being a work in progress on profitability and capital discipline. The company is growing in both consumer and enterprise learning, supported by rising employer acceptance of micro-credentials and recurring revenue streams. It also carries risks around heavy partner reliance, ongoing losses and recent shareholder dilution. Recent news around its acquisition of Udemy, a US$100m investment in AI-focused LearnVector and ambitious synergy and margin targets show management leaning hard into scale and AI driven personalisation, even as Q2 2026 losses and guidance disappointed the market. The key question is whether Coursera’s combination of growth, AI and recurring enterprise contracts can justify the current valuation and analysts’ future expectations.

Coursera’s push into AI powered learning and recurring enterprise contracts could be masking a much bigger shift in its earnings profile. Get the full picture in the analyst forecasts for Coursera

The three stocks covered here are just a starting point. The full Healthy high growth potential screener highlights 259 more companies that analysts currently link to strong earnings growth expectations and solid financial footing through the Healthy high growth potential screener. Use Simply Wall St to identify and analyze the specific catalysts and narratives that matter to you so you can focus on the highest conviction opportunities for your watchlist.

Take Control of Your Investment Journey

If Corcept Therapeutics or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly

Market momentum can flip fast, and the best breakout stories often get noticed by the crowd only after the main move has already happened. Scan for fresh, under the radar ideas while it matters and consider them before they become widely followed.

• Identify companies with strong balance sheets before they receive wider attention by scanning the list of solid balance sheet and fundamentals (45 results), which keeps financially fragile names off your shortlist.
• Monitor structural demand in critical materials by tracking producers in the 8 top copper producer stocks, which focuses on companies positioned in long term resource security themes.
• Review changing power demand by looking at infrastructure stocks in the 35 power grid technology and infrastructure stocks, which highlights businesses involved in grid upgrades while many investors still look elsewhere.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.